Status:
COMPLETED
Adherence Risk Indicator Validation Study
Lead Sponsor:
Fisher and Paykel Healthcare
Conditions:
Obstructive Sleep Apnea
Eligibility:
All Genders
18+ years
Brief Summary
While continuous positive airway pressure (CPAP) is the gold standard treatment of obstructive sleep apnea (OSA), this therapy is often discontinued or not used optimally. The adherence risk indicator...
Eligibility Criteria
Inclusion
- ≥ 18years of age
- Diagnosed with OSA (AHI \>5 events/hour) and eligible for CPAP (fixed or auto) treatment under local requirements
- Naïve to CPAP therapy, i.e. have not been prescribed CPAP in the past 5 years
Exclusion
- Contraindicated for CPAP therapy
- Medically unstable condition/diagnosis that is not yet under control
- Co-existing sleep disorder (however clinically diagnosed insomnia can be included in the study)
- PLMA (Periodic Limb Movement Activity) Index greater than 15/hr
- Home titration of longer than 5 days
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT02230085
Start Date
September 1 2014
End Date
December 1 2015
Last Update
March 3 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
EverythingCPAP
Boise, Idaho, United States, 83704